Thank you all for the tremendous hard work and initiatives that help to maintain Histio UK’s Information and Research Programmes.
We will continue our work towards early diagnosis, effective treatment and a cure.
“No-one should die of Histiocytosis”
A Preliminary Policy Proposal
‘Salvage of histiocytic neoplasms causing life-threatening disease with mitogen-activated protein kinase (MAPK) inhibitors’ has been submitted to NHS England on 2nd November. This advises the NHS to develop a commissioning policy for access to Vemurafenib, Dabrafenib, Cobimetinib and Trametinib.The next step is a review by the Specialised Commissioning Panel to determine whether the policy will be adopted onto the work flow. From this point it will take at least 12 months for NHSE to develop a commissioning policy after wide consultation with all of the relevant stake holders, including a number of patients, families and Histio UK.
Histiocytosis UK is dedicated to promoting and funding scientific research into uncovering not only the causes of all histiocytic diseases, which include Langerhans’s Cell Histiocytosis and Haemophagocytic Lymphohistiocytosis, but also ensuring early diagnosis, effective treatment and a cure.
Histio UK also aims to support patients and their families as well as raise public and professional awareness of histiocytic disorders. Its team of Trustees include the UK’s leading paediatric LCH and HLH specialists.
